Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Lonza Inks Biotech Manufacturing Pacts

by Rick Mullin
November 2, 2009 | A version of this story appeared in Volume 87, Issue 44

Swiss contract drugmaker Lonza will manufacture Alnara Pharmaceuticals’ lead product, liprotamase, at its site in Kourˇim, Czech Republic. The drug is a pancreatic-enzyme replacement therapy for patients with pancreatic insufficiency. Lonza also acquired a stake in Cilian, a German biotech company that uses the abilities of ciliates, eukaryotic single-cell organisms, to produce therapeutic proteins. The deal provides Lonza with access to technology and first right of refusal for commercial manufacturing of products.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.